Journal article
Screening, referral and treatment for depression in patients with coronary heart disease: A consensus statement from the national heart foundation of Australia
DM Colquhoun, SJ Bunker, DM Clarke, N Glozier, DL Hare, IB Hickie, J Tatoulis, DR Thompson, GH Tofler, A Wilson, MG Branagan
Medical Journal of Australia | Published : 2013
DOI: 10.5694/mja13.10153
Abstract
In 2003, the National Heart Foundation of Australia position statement on "stress" and heart disease found that depression was an important risk factor for coronary heart disease (CHD). This 2013 statement updates the evidence on depression (mild, moderate and severe) in patients with CHD, and provides guidance for health professionals on screening and treatment for depression in patients with CHD. • The prevalence of depression is high in patients with CHD and it has a significant impact on the patient's quality of life and adherence to therapy, and an independent effect on prognosis. Rates of major depressive disorder of around 15% have been reported in patients after myocardial infarction..
View full abstractGrants
Awarded by NHMRC Australia Fellowship
Funding Acknowledgements
David Colquhoun has been a member of advisory groups for industry including for MSD, Pfizer (Lipid advisory group), Abbott (Fish oil advisory group). He has undertaken research for Boehringer Ingelheim (RELY trial), Abbott (SCOUT trial), BMS (SAVOR trial), and for Sanofi-Aventis (PALLAS Trial and ORIGIN Trial). He is also a member of the Gallipoli Research Foundation Scientific Committee. David Hare developed the CDS, and has received research, fellowship and consultancy funds from the NHMRC, the NHFA, the Austin Medical Research Foundation, beyondblue, and Diabetes Australia. He has received payment for research projects, consultancies, travel, advisory board memberships and lectures from industry including Abbott, Amgen, AstraZeneca, Biotronic, BMS, Boehringer Ingelheim, CSL-Biotherapies, Hoffmann-LaRoche, Hospira, Lundbeck (Denmark), Medtronic, Menarini, Merck KA (Germany), Merck (US), MSD, Pfizer, Roche, Sanofi-Aventis, Servier and Wyeth. Ian Hickie was supported by an NHMRC Australia Fellowship (No. 464914). He was a director of headspace: the national youth mental health foundation until January 2012. He is the executive director of the Brain and Mind Research Institute, which operates two early intervention youth services under contract to headspace. He is a member of the new Australian National Mental Health Commission and was previously the CEO of beyondblue. He has led a range of community-based and pharmaceutical industry-supported depression awareness and education and training programs, and depression and other mental health research projects supported by a variety of pharmaceutical partners. His current investigatorinitiated studies are supported by Servier and Pfizer. He has received honoraria for his contributions to professional educational seminars supported by the pharmaceutical industry (including Servier, Pfizer, AstraZeneca, Janssen and Eli Lilly). Nick Glozier has been funded under a strategic research grant program by beyondblue and the NHFA. He has received other depression-related research funds from the NHMRC, beyondblue, the Australian Research Council and Servier Laboratories. He has received travel and consultancy fees from Servier Laboratories. There are no relevant disclosures for the other authors.